Piramal Pharma 6th AGM on 30 July 2026; FY26 Annual Report filed

Board & Shareholder Meetings View source PDF

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+5.5%1-day move

₹168.76

prior close

₹176.32

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.2-0.2——+5.5+3.7-0.5+2.0+4.6+1.9+7.4———

Up moveDown movePending

AI summary

Piramal Pharma filed the notice for its 6th AGM on 30 July 2026 at 3 pm via video conferencing, along with the FY26 Annual Report and BRSR. FY26 was a transitional year. Revenue from operations stood at Rs 8,869 crore, gross contribution at Rs 5,631 crore, and EBITDA at Rs 1,135 crore with capex of Rs 890 crore. CDMO revenue was Rs 4,915 crore hit by inventory destocking and weak early-stage orders. CHG revenue was Rs 2,703 crore led by the Kenalog acquisition and PCH grew 17 percent to Rs 1,274 crore. Company committed US$90 million to expand Lexington and Riverview sites.

Likely market impact

Routine AGM and annual report filing. FY26 was muted but H2 recovery in CDMO order inflows and capacity investments support FY27 growth outlook.